Roth Capital Reiterates Buy On Acura Following Positive PK Results
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a $1.50 price target, following preliminary results of the company’s Study 302, which demonstrated that AVERSION hydrocodone with acetaminophen (AVERSION H/A) meets FDA requirements for bioequivalence to reference drug Norco.
Arce noted, “Study AP-ADF-302 measured blood concentration of hydrocodone and acetaminophen (APAP) in 36 healthy adults in fed and fasted states. In this key study, AVERSION H/A met the objective of conformance with FDA standards for bioequivalence when compared to the reference drug Norco, when taken in the fasted state. However, in the fed state, AVERSION H/A demonstrated a 13.7% and 34.4% average reduction in peak blood concentration for hydrocodone and APAP, respectively, compared to Norco in the fasted state. These food effect results are consistent with the AVERSION technology and also the known effect of food on acetaminophen in general. Acura does not expect the reductions to have a meaningful clinical impact.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a total average return of 7.0% and a 19.4% success rate. Arce has a -12.7% average return when recommending ACUR, and is ranked #1062 out of 3313 analysts.